Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?

Overview of attention for article published in Expert Opinion on Pharmacotherapy, January 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 2 news outlets

guideline: 1 clinical guideline source

Readers on

mendeley: 8 Mendeley

So far, Altmetric has seen 2 news stories from 2 outlets.

Intravesical gemcitabine/docetaxel as an alternative therapy for patients with non-muscle-invasive bladder cancer

M 3 Medical, 26 Feb 2024

Bladder cancer is one of the more common cancers worldwide. It is considered a major health care problem with a high financial…

Intravesical gemcitabine/docetaxel as an alternative therapy for patients with non-muscle-invasive bladder cancer

MedicalXpress, 23 Feb 2024

Bladder cancer is one of the more common cancers worldwide. It is considered a major health care problem with a high financial…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.